Sarepta Therapeutics (SRPT) Tops Q3 EPS by 7c; Raises FY Revenue outlook

Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($0.78), $0.07 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $46 million versus the consensus estimate of $40.77 million.

GUIDANCE:

Sarepta Therapeutics sees FY2017 revenue of $150-155 million, versus the consensus of $139.45 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance